CELLINK is carrying out stock split (4:1)

January 13, 2020 is the record date for the split (4:1) as decided by the AGM December 18, 2019.

The AGM has decided to carry out the stock split, where each existing share is divided into four new shares. The record date is January 13, 2020.

The number of shares after splitting with be 38,984,776; 1,500,000 series A shares and 37,484,776 series B shares. The quota value will amount to 0.025 kronor. As a result of the stock split, shares will receive new ISIN codes. The new ISIN code for B shares is SE0013647385.

The last trading day for B shares with the old ISIN code before the split is January 9, 2020 and the first trading day after the split with the new ISIN code is January 10, 2020.

The stock split will be carried out automatically through Euroclear Sweden AB; share owners do not need to take any action. Shares received in the stock split are expected to be registered in shareholders' security accounts January 14, 2020.

For more information, please contact:

Erik Gatenholm, CEO                                                                               Gusten Danielsson, CFO

EU: +46 73 267 00 00                                                                             EU: +46 70 991 86 04
US: +1 (650) 515 5566                                                                            US: +1 (857) 332 2138

Email: eg@cellink.com                                                                              Email: gd@cellink.com


CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the companys certified adviser, available by phone at +46 846 383 00 and by email at certifiedadviser@penser.se.

About Us

Founded in 2016, CELLINK AB (publ) is the leading bioconvergence company in world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 700 publications. CELLINK is creating the future of medicine. Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm under CLNK B.


Documents & Links